Viral Hepatitis

You have free access to this content

Public health impact of antiviral therapy for hepatitis C in the United States†

  1. Michael L. Volk‡,*,
  2. Rachel Tocco,
  3. Sameer Saini,
  4. Anna S.F. Lok

Article first published online: 10 AUG 2009

DOI: 10.1002/hep.23220

Issue

Hepatology

Hepatology

Volume 50, Issue 6, pages 1750–1755, December 2009

Additional Information

How to Cite

Volk, M. L., Tocco, R., Saini, S. and Lok, A. S.F. (2009), Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology, 50: 1750–1755. doi: 10.1002/hep.23220

Author Information

  1. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI

  1. ‡

    fax: 734-936-8944.

*Division of Gastroenterology and Hepatology, University of Michigan Health System, 7C27 NIB, 300 N. Ingalls, Ann Arbor, MI 48109

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 20 NOV 2009
  2. Article first published online: 10 AUG 2009
  3. Accepted manuscript online: 10 AUG 2009 12:00AM EST
  4. Manuscript Accepted: 3 JUL 2009
  5. Manuscript Received: 14 MAY 2009

Funded by

  • Greenview Foundation
  • American Gastroenterological Association

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (273K)

References

  • 1
    Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995–2004. HEPATOLOGY 2008; 47: 1128–1135.
  • 2
    Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997–2006. Am J Transplant 2008; 8: 958–976.
  • 3
    Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372–1380.
  • 4
    Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. HEPATOLOGY 2005; 41: 790–800.
  • 5
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331–338.
  • 6
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562–1569.
  • 7
    Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 2001; 323: 1151–1155.
  • 8
    Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 1153–1162.
  • 9
    Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004; 11: 148–156.
  • 10
    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677–684.
  • 11
    Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483–491.
  • 12
    Ong JP, Collantes R, Pitts A, Martin L, Sheridan M, Younossi ZM. High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol 2005; 39: 826–830.
  • 13
    Swartz MS, Swanson JW, Hannon MJ, Bosworth HS, Osher FC, Essock SM, et al. Regular sources of medical care among persons with severe mental illness at risk of hepatitis C infection. Psychiatr Serv 2003; 54: 854–859.
  • 14
    Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat 2001; 8: 377–383.
  • 15
    Shehab TM, Orrego M, Chunduri R, Lok AS. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003; 98: 639–644.
  • 16
    Shiffman ML. A balancing view: we cannot do it alone. Am J Gastroenterol 2007; 102: 1841–1843.
  • 17
    Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288–292.
  • 18
    Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, et al. Predictors of treatment in patients with chronic hepatitis C infection — role of patient versus nonpatient factors. HEPATOLOGY 2007; 46: 1741–1749.
  • 19
    Rosenberg DM, Cook SF, Lanza LL. Health care, treatment patterns and cost of services for patients infected with chronic hepatitis C virus in a large insured New England population. J Viral Hepat 2000; 7: 361–367.
  • 20
    Newman J, Cecchini A. Wolters Kluwer Weekly Prescription Data; February 27, 2009. Oppenheimer Equity Research Industry Update: Healthcare/Specialty Pharmaceuticals 2009; March 9, 2009.
  • 21
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705–714.
  • 22
    Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis — United States, 2007. MMWR Surveill Summ 2009; 58: 1–27.
  • 23
    Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107–115.
  • 24
    Arias E. United States life tables, 2004. Natl Vital Stat Rep 2007; 56: 1–39.
  • 25
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 1335–1374.
  • 26
    Ezzati TM, Massey JT, Waksberg J, Chu A, Maurer KR. Sample design: Third National Health and Nutrition Examination Survey. Vital Health Stat 2 1992: 1–35.
  • 27
    Lettmeier B, Muhlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528–536.
  • 28
    Hoofnagle JH. A step forward in therapy for hepatitis C. N Engl J Med 2009; 360: 1899–1901.
  • 29
    Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am J Public Health 2003; 93: 635–641.
  • 30
    U.S. Preventive Services Task Force. Screening for Hepatitis C: Recommendation Statement. Rockville, MD; 2004.
  • 31
    Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760–764.
View Full Article with Supporting Information (HTML) Get PDF (273K)